Addressing the challenges of poor biocompatibility and degradability of artificial drug carriers and poor stability of natural monomer gels in the current pharmaceutical market, this study utilized green natural sodium alginate (SA) and humic acid (HA) as raw materials. SA/HA-Ca hydrogel spheres were prepared using Ca as a crosslinking agent and loaded with l-ascorbic acid (L-AA), and the drug-retardation study was conducted using the droplet method. Various analysis techniques confirmed the formation of a three-dimensional network structure through coordination between HA, SA, and Ca, resulting in hydrogel spheres with good thermal stability. Meanwhile, the drug-loading rate, swelling, and in vitro drug release of SA/HA-Ca gel spheres were investigated. Results showed that the hydrogel spheres exhibited strong pH responsiveness and satisfactory pore structure favorable for the loading of L-AA. The solubility of the SA/HA-Ca hydrogel in buffer solutions at pH = 1.4 and 7.4 was 1.7315 and 5.1235 g/g, respectively, while the swelling kinetics followed a second-order swelling kinetic equation; the maximum release of L-AA was 23.67 % and 82.64 %. The release profiles of L-AA from different drug-loaded gels conformed to Langmuir's quasi-primary and quasi-secondary kinetic models. In conclusion, this study provides a theoretical basis for achieving slow drug release using SA/HA-Ca.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2024.135777DOI Listing

Publication Analysis

Top Keywords

drug release
12
hydrogel spheres
12
l-ascorbic acid
8
sa/ha-ca hydrogel
8
release sa/ha-ca
8
release
5
synthesis characterization
4
characterization ph-responsive
4
ph-responsive sodium
4
sodium alginate/humic
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.

Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.

Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Aptah Bio Inc., San Carlos, CA, USA.

Background: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, China.

Background: Glucagon-like peptide 1 (GLP-1) is a peptide hormone that plays several physiological roles in treating diabetes and in protecting the brain. Recent clinical trials testing 4 different GLP-1 class drugs in phase 2 trials showed a clear correlation between neuroprotection and the ability to cross the BBB. Exenatide and Lixisenatide both showed excellent protective effects in patients Parkinson's disease (PD) and both drugs can readily cross the BBB.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.

Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Yonsei University, Incheon, Incheon, Korea, Republic of (South).

Background: Cyclin Y (CCNY) is a member of cyclin protein family inhibiting long-term synaptic plasticity, which is related to the learning and memory function in neuronal system. Recently, CCNY has been reported to associate with the cognitive deficits in Alzheimer's disease (AD).

Method: In this study, we discovered PFTAIRE peptide to diminish CCNY protein level and to ameliorate cognitive dysfunction in AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!